- Home
- BDL vs COEP Comparison
BDL vs COEP Comparison
Compare BDL & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDL | COEP |
|---|---|---|
| Founded | 1959 | 2017 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.6M | 72.7M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | BDL | COEP |
|---|---|---|
| Price | $34.42 | $12.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 573.0 | ★ 32.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 49.72 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $205,248,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $80.03 | ★ N/A |
| Revenue Growth | ★ 8.99 | N/A |
| 52 Week Low | $22.61 | $6.32 |
| 52 Week High | $35.98 | $21.41 |
Technical Indicators
Market Signals| Indicator | BDL | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 45.69 |
| Support Level | $29.56 | $10.98 |
| Resistance Level | $34.61 | $13.23 |
| Average True Range (ATR) | 0.29 | 0.94 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 100.00 | 41.06 |
Price Performance
Historical ComparisonAbout BDL Flanigan's Enterprises Inc.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.